Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Carmen Mota Reyes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-7483-1352; OpenAlex author ID A5112966564. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers · 2025: 5 papers · 2026: 2 papers

Papers 22

  1. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  2. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. First author DOI 10.1016/j.xcrm.2025.102546↗
  3. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  4. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Last author DOI 10.1016/j.canlet.2025.217894↗
  5. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  6. Pancreatic cancer cells infiltrate nerves through TGFbeta1-driven perineural epithelial-to-mesenchymal-like transdifferentiation. Co-author DOI 10.1016/j.neo.2025.101126↗
  7. Neural crossroads of pancreatic cancer: how nociceptors drive tumor progression and immune evasion. Co-author DOI 10.1038/s41422-025-01124-5↗
  8. Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunother… Co-author DOI 10.1002/cac2.12496↗
  9. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  10. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Co-author DOI 10.1038/s41598-024-77010-8↗
  11. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2024.1378190↗
  12. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  13. Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. Co-author DOI 10.1159/000519755↗
  14. Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Co-author DOI 10.3390/cancers14194582↗
  15. Innervated mouse pancreas organoids as an ex vivo model to study pancreatic neuropathy in pancreatic cancer. Co-author DOI 10.1016/j.xpro.2021.100935↗
  16. Chemokines: the (un)usual suspects in pancreatic cancer neural invasion. First author DOI 10.1038/s41575-020-0329-1↗
  17. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? First author DOI 10.1007/s00423-020-01946-4↗
  18. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Co-author DOI 10.1158/1078-0432.ccr-19-1864↗
  19. Future directions of neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.18632/oncoscience.506↗
  20. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2017.03.003↗
  21. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.suronc.2017.01.007↗
  22. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Co-author DOI 10.1073/pnas.1606909114↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 22 shared papers, 2017–2026 · strength 3.85
  2. Guralp Onur Ceyhan · 14 shared papers, 2017–2026 · strength 2.00
  3. Helmut Friess · 11 shared papers, 2017–2026 · strength 1.96
  4. Helmut Frieß · 8 shared papers, 2017–2025 · strength 1.16
  5. Okan Safak · 6 shared papers, 2020–2025 · strength 0.96
  6. Kaan Çifcibaşı · 5 shared papers, 2022–2026 · strength 0.91
  7. Dieter Saur · 5 shared papers, 2023–2026 · strength 0.90
  8. Rüdiger Göß · 5 shared papers, 2017–2025 · strength 0.82
  9. Alexander Muckenhuber · 5 shared papers, 2020–2025 · strength 0.81
  10. Hana Algül · 5 shared papers, 2017–2026 · strength 0.69
  11. Roland Rad · 4 shared papers, 2023–2026 · strength 0.68
  12. Kıvanç Görgülü · 4 shared papers, 2023–2026 · strength 0.64
  13. Linhan Ye · 4 shared papers, 2021–2025 · strength 0.57
  14. Achim Krüger · 4 shared papers, 2017–2026 · strength 0.54
  15. Ilaria Pergolini · 3 shared papers, 2024–2025 · strength 0.54
  16. Lei Ren · 3 shared papers, 2020–2025 · strength 0.44
  17. Maximilian Kießler · 3 shared papers, 2023–2024 · strength 0.44
  18. Marina Lesina · 3 shared papers, 2017–2026 · strength 0.37
  19. Didem Karakaş · 2 shared papers, 2025–2026 · strength 0.35
  20. Stefanie Bärthel · 2 shared papers, 2023–2026 · strength 0.33
  21. Qiaolin Li · 2 shared papers, 2023–2024 · strength 0.29
  22. Saliha Elif Yıldızhan · 2 shared papers, 2023–2025 · strength 0.28
  23. Roland Michael Schmid · 2 shared papers, 2023–2025 · strength 0.28
  24. Stephan Schorn · 3 shared papers, 2017–2024 · strength 0.27
  25. Martin Loveček · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.